Immix Biopharma (NASDAQ: IMMX)

Last close As at 21/02/2025

USD1.78

−0.10 (−5.32%)

Market capitalisation

USD52m

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Latest Insights

View More

Healthcare | Flash

Immix Biopharma — NXC-201 receives FDA RMAT designation

Healthcare | Comment

Immix (NASDAQ: IMMX) presents positive data in ALA

Healthcare | Flash note

Immix Biopharma — US CAR-T trial progresses to dose expansion

Scientist using protective robber gloves for handling substances and experiments

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Analyst, Healthcare

Key Management

  • Dr Ilya Rachman

    CEO

  • Gabriel Morris

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free